Group 1 - The core theme of the upcoming "10th Zhitong Financial Capital Market Annual Conference" is "Winning the Hong Kong Stock Surge: Bullish Outlook for 2026," focusing on the potential of Chinese assets amid a new technology-driven bull market [1] - The Hang Seng Index surged by 28% in a single quarter, while the Hang Seng Tech Index rebounded over 50% year-to-date, indicating a significant capital influx into undervalued Chinese assets [1] - The conference will feature prominent speakers, including economists and fund managers, who will discuss cross-border capital flows and relative valuation opportunities in the Hong Kong stock market [2] Group 2 - The afternoon session will focus on innovative pharmaceuticals, with companies like Deke Pharma and He Yu sharing insights on their latest clinical developments and commercialization strategies [3] - A diverse lineup of over 80 listed companies will participate in roadshows, providing investors with opportunities for in-depth discussions and identifying quality investment targets [4] Group 3 - The "3rd Overseas Fund Summit" will take place on December 4, featuring discussions on global capital allocation strategies and the impact of geopolitical shifts on investment [5] - The event will include four strategic roundtable discussions, addressing topics such as cognitive warfare and the mission of capital in a post-scarcity era [6] - The conference will conclude with the presentation of the New Intelligence Awards, showcasing the evolution of investment strategies from present to future [6] Group 4 - The event will continue in Hong Kong on December 5, maintaining a dual-city format that emphasizes the synergy between technological breakthroughs and global capital trends [6] - The conference aims to explore new patterns, tracks, and dividends arising from the new technological revolution, inviting participants to engage in high-level discussions [6]

Core Viewpoint - 加科思-B (01167.HK) experienced a significant increase in stock price, rising over 7% in early trading and currently up by 5.94% at HKD 7.31, with a trading volume of HKD 16.91 million [2] Summary by Category - **Stock Performance** - The stock price of 加科思-B rose over 7% in early trading [2] - As of the latest update, the stock is up 5.94%, priced at HKD 7.31 [2] - The trading volume reached HKD 16.91 million [2]

Group 1 - The core point of the article is that 加科思-B (01167) has established a co-CEO system, with current Chairman and CEO Dr. Wang Yinxiang and current Chief Medical Officer Dr. Wang Yi sharing the CEO responsibilities, aiming to enhance global strategic planning and market expansion in innovative drug development [1] - Following the announcement, 加科思-B's stock price rose over 7% in early trading, with a current increase of 5.94% to HKD 7.31 and a trading volume of HKD 16.91 million [1] - 加科思-B has signed a capital increase and equity transfer agreement with 海松资本 and an industry partner, where 海松资本 will pay RMB 125 million as an initial payment and RMB 75 million as a milestone payment to acquire 80% of 加科瑞康, leading to a reduction of 加科思's stake in 加科瑞康 to 10% [1] Group 2 - The new management structure will allow Dr. Wang Yinxiang to continue leading the company's global strategic planning and major decision-making, while Dr. Wang Yi will focus on overseas market expansion, international collaboration, and clinical development [1] - The divestment of non-core assets will enable 加科思-B to concentrate more on the oncology sector and improve its cash flow [1]

Group 1 - The core point of the article is the establishment of a co-CEO system at 加科思-B, with Dr. Wang Yinxiang and Dr. Wang Yi taking on the roles to enhance global strategic planning and market expansion [1][1][1] - Following the announcement, 加科思-B's stock price increased by over 7%, reaching 7.31 HKD with a trading volume of 16.91 million HKD [1][1][1] - The company has signed an agreement with 海松资本 for a capital increase and equity transfer, where 海松资本 will pay a total of 2 billion RMB for an 80% stake in 加科瑞康, allowing 加科思 to focus more on its core oncology business [1][1][1] Group 2 - Dr. Wang Yinxiang will continue to lead the company's global strategy and major decisions, while Dr. Wang Yi will focus on international market development and clinical work [1][1][1] - The divestment of non-core assets is expected to strengthen the company's cash flow and strategic focus in the oncology sector [1][1][1]

Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on November 13, 2025, with China Feihe (06186) leading in both the number of shares repurchased and the total amount spent on buybacks, amounting to 20 million shares and 87.858 million yuan respectively [1][2]. Group 1: Buyback Details - China Feihe (06186) repurchased 20 million shares for 87.858 million yuan, with a year-to-date total of 117 million shares, representing 1.294% of its total share capital [2]. - COSCO Shipping Holdings (01919) repurchased 3 million shares for 42.9502 million yuan, with a year-to-date total of 25.188 million shares, accounting for 0.875% of its total share capital [2]. - China International Marine Containers (02039) repurchased 2.8054 million shares for 20.01 million yuan, with a year-to-date total of 3.66303 million shares, representing 1.190% of its total share capital [2]. Group 2: Other Notable Buybacks - Sinopec Limited (00386) repurchased 3.468 million shares for 15.3039 million yuan, with a year-to-date total of 139 million shares, accounting for 0.110% of its total share capital [2]. - Yip's Chemical Holdings (06826) repurchased 39,500 shares for 1.1077 million yuan, with a year-to-date total of 580,100 shares, representing 1.482% of its total share capital [3]. - Kangji Medical Holdings (01681) repurchased 20 million shares for 300,000 yuan, with a year-to-date total of 9.898 million shares, accounting for 11.627% of its total share capital [3].

Group 1 - The company, 加科思-B (01167), announced a share buyback plan, intending to repurchase 72,000 shares at a total cost of HKD 498,300 [1]

Core Viewpoint - The company, 加科思-B (01167), announced a share buyback plan, indicating a strategic move to enhance shareholder value through the repurchase of its own shares [1] Group 1 - The company will spend HKD 498,300 to repurchase 72,000 shares [1]

Group 1 - The company, 加科思-B (01167.HK), announced a share buyback plan on November 13, 2025, involving an expenditure of HKD 500,000 to repurchase 72,000 shares [1] - The buyback price per share is set between HKD 6.92 and HKD 6.93 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 加科思藥業集團有限公司 呈交日期： 2025年11月13日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01167 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 ...

Summary of Key Points Core Viewpoint - A total of 30 companies conducted share buybacks on November 12, 2025, with China COSCO Shipping Holdings (01919) leading in terms of buyback amount and quantity. Group 1: Buyback Details - China COSCO Shipping Holdings (01919) repurchased 3 million shares for a total of 43.1382 million yuan, representing 0.770% of its total share capital [1][2] - Sinopec Limited (00386) repurchased 3.708 million shares for 16.5210 million yuan, accounting for 0.110% of its total share capital [2] - China International Marine Containers (02039) repurchased 2 million shares for 14.1189 million yuan, which is 1.090% of its total share capital [2] Group 2: Other Notable Buybacks - China Feihe Limited (06186) repurchased 2 million shares for 8.8511 million yuan, representing 1.074% of its total share capital [2] - AAC Technologies Holdings (02018) repurchased 221,500 shares for 8.8302 million yuan, which is 0.186% of its total share capital [2] - Linklogis Inc. (09959) repurchased 1,208,000 shares for 3.7894 million yuan, accounting for 4.685% of its total share capital [2] Group 3: Additional Companies - Mobi Development (00947) repurchased 50,000 shares for 8.0500 million yuan, which is 0.222% of its total share capital [3] - Tianfu (06868) repurchased 10,000 shares for 30,000 yuan, representing 0.051% of its total share capital [3] - Hylink Digital Solutions (01586) repurchased 80,000 shares for 22,100 yuan, accounting for 4.305% of its total share capital [3]